Progyny, Inc. $PGNY Shares Sold by Capital Fund Management S.A.

Capital Fund Management S.A. trimmed its holdings in Progyny, Inc. (NASDAQ:PGNY) by 28.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,791 shares of the company’s stock after selling 30,897 shares during the quarter. Capital Fund Management S.A. owned about 0.09% of Progyny worth $1,689,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Nordea Investment Management AB raised its position in shares of Progyny by 0.6% during the 2nd quarter. Nordea Investment Management AB now owns 183,362 shares of the company’s stock worth $4,052,000 after buying an additional 1,140 shares in the last quarter. Voya Investment Management LLC boosted its holdings in shares of Progyny by 258.2% in the first quarter. Voya Investment Management LLC now owns 185,495 shares of the company’s stock valued at $4,144,000 after acquiring an additional 133,703 shares in the last quarter. Millennium Management LLC increased its stake in shares of Progyny by 7.5% during the first quarter. Millennium Management LLC now owns 1,302,890 shares of the company’s stock valued at $29,107,000 after acquiring an additional 90,367 shares during the period. Acadian Asset Management LLC raised its holdings in Progyny by 243.6% during the first quarter. Acadian Asset Management LLC now owns 205,650 shares of the company’s stock worth $4,589,000 after purchasing an additional 145,802 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd lifted its position in Progyny by 88.0% in the second quarter. Y Intercept Hong Kong Ltd now owns 56,196 shares of the company’s stock worth $1,236,000 after purchasing an additional 26,310 shares during the period. Institutional investors own 94.93% of the company’s stock.

Insider Activity at Progyny

In other news, CEO Peter Anevski acquired 79,500 shares of the stock in a transaction on Thursday, November 13th. The shares were purchased at an average cost of $24.29 per share, for a total transaction of $1,931,055.00. Following the transaction, the chief executive officer owned 680,251 shares in the company, valued at approximately $16,523,296.79. This trade represents a 13.23% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Mark S. Livingston sold 21,303 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $25.50, for a total value of $543,226.50. Following the completion of the sale, the chief financial officer owned 48,358 shares of the company’s stock, valued at $1,233,129. The trade was a 30.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 9.40% of the company’s stock.

Analyst Ratings Changes

PGNY has been the topic of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 price target (up from $26.00) on shares of Progyny in a research report on Friday, August 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Progyny in a research report on Wednesday, October 8th. KeyCorp raised shares of Progyny from a “sector weight” rating to an “overweight” rating and set a $30.00 price target for the company in a report on Tuesday, November 11th. JPMorgan Chase & Co. lifted their price objective on shares of Progyny from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 11th. Finally, Canaccord Genuity Group increased their target price on shares of Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a research note on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Progyny presently has an average rating of “Moderate Buy” and an average price target of $27.33.

Progyny Trading Down 1.6%

Shares of PGNY opened at $24.15 on Friday. The business’s 50-day moving average price is $21.99 and its 200 day moving average price is $22.21. The stock has a market capitalization of $2.08 billion, a P/E ratio of 38.33, a P/E/G ratio of 1.93 and a beta of 0.97. Progyny, Inc. has a 1-year low of $13.86 and a 1-year high of $27.51.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, November 6th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.39 by $0.06. The company had revenue of $313.35 million during the quarter, compared to analysts’ expectations of $299.23 million. Progyny had a net margin of 4.46% and a return on equity of 10.71%. The business’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same period last year, the company posted $0.11 earnings per share. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. On average, research analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.